10.05.2024  22:10:00 Zm. -0,31 Wolumen Bid01:54:49 Ask01:54:49 Kapitalizacja Rynkowa St. dywidendy Wskaźnik C/Z
30,71USD -1,00% 782 730
Obrót: 17,59 mln
30,13Wolumen Bid: 100 31,50Wolumen Ask: 200 4,19 mldUSD 3,13% -

Opis działalności

Perrigo Company plc, a top five global over-the-counter ("OTC") consumer goods and pharmaceutical company, offers patients and customers high quality products at affordable prices. From its beginnings in 1887 as a packager of generic home remedies, Perrigo, headquartered in Ireland, has grown to become the world's largest manufacturer of OTC products and supplier of infant formulas for the store brand market. The Company is also a leading provider of generic extended topical prescription products and receives royalties from Multiple Sclerosis drug Tysabri®. Perrigo provides Quality Affordable Healthcare Products® across a wide variety of product categories and geographies primarily in North America, Europe, and Australia, as well as other markets, including Israel, China and Latin America.
 

Zarząd & Rada nadzorcza

CEO
Murray S. Kessler
Zarząd
Raymond Silcock, Grainne Quinn, James E. Dillard III, Rob Willis, Ron Janish, Svend Andersen, Todd W. Kingma, Tom Farrington
Rada nadzorcza
Rolf Classon, Adriana Karaboutis, Bradley Alford, Donal O'Connor, Erica L. Mann, Geoffrey M. Parker, Jeff Kindler, Katherine Doyle, Murray S. Kessler, Orlando D. Ashford, Theodore R. Samuels
 

Dane firmy

Nazwa: Perrigo Company plc
Adres: Treasury Building, Lower Grand Canal St.,IRL-Dublin 2, Ireland
Telefon: +1-353-1709-4000
Fax: -
E-mail: -
Internet: www.perrigo.com/
Przemysł: Służba zdrowia
Sektor: Przemysł Farmaceutyczny
Podsektor: Przemysł Farmaceutyczny
Koniec roku finansowego: 31.12
Free float: 67,70%
Data IPO: -

Relacje inwestorskie

Nazwa: Bradley Joseph
Telefon: +1-269-686-3373
Fax: -
E-mail: bradley.joseph@perrigo.com

Główni akcjonariusze

Freefloat
 
67,70%
T. Rowe Price Associates, Inc.
 
13,20%
The Vanguard Group
 
11,50%
BlackRock Inc.
 
7,60%